Prosthetic heart valve is a device that acts as an artificial heart valve for treatment of patients suffering from valvular heart diseases. Valvular heart diseases result in malfunction of valves of the human heart.
The global prosthetic heart valve market was valued at $3,874 million in 2016, and is expected to reach at $8,392 million by 2023, growing at a CAGR of 11.4%. The market is driven by the growth in incidences of cardiac disorders, increase in geriatric population, rise in patient awareness, demand for minimally invasive cardiovascular surgeries, technological advancements in heart repair & replacement devices, and surge in number of transcatheter heart valve surgery centers. However, high cost of devices and risks associated with prosthetic valve implantation procedure and stringent approval process for prosthetic valves hamper the market growth. Conversely, use of transcatheter heart valves for new indications and growth opportunities in emerging economies of Asia-Pacific and LAMEA are expected to provide several opportunities for market growth during the forecast period.
The report segments the market based on product and region. Based on product, it is divided into mechanical heart valve, tissue heart valve, and transcatheter heart valve. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, The Netherlands, Turkey, Belgium, Switzerland, Russia, Denmark, Austria, Norway, Poland, Sweden, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, Malaysia, Republic of Korea, New Zealand, Singapore, Thailand, Vietnam, Taiwan, Indonesia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, United Arab Emirates (UAE), Libya, Algeria, Kenya, Kuwait, Jordan, Sudan, Morocco, Israel, Zimbabwe, Mauritius, Oman, Argentina, Iran, Iraq, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis and comprehensive analysis of all geographical regions from 2016 to 2023, enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis by product helps understand the various types of devices used for treatment and to monitor the cardiac patients.
Key players are profiled and their strategies are analyzed thoroughly to understand competitive outlook of the global market.
KEY MARKET SEGMENTS
BY PRODUCT
Mechanical Heart Valve
Tissue Heart Valve
Stented Tissue Heart Valve
Stentless Tissue Heart Valve
Transcatheter Heart Valve
BY REGION
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
The Netherlands
Turkey
Belgium
Switzerland
Russia
Denmark
Austria
Norway
Poland
Sweden
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Malaysia
Republic of Korea
New Zealand
Singapore
Thailand
Vietnam
Taiwan
Indonesia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
United Arab Emirates (UAE)
Libya
Algeria
Kenya
Kuwait
Jordan
Sudan
Morocco
Israel
Zimbabwe
Mauritius
Oman
Argentina
Iran
Iraq
Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Abbott Laboratories
Medtronic plc.
Medical Technology Est.
Boston Scientific Corporation
Micro Interventional Devices, Inc.
Direct Flow medical, Inc.
Edwards Lifesciences Corporation
LivaNova PLC
JenaValve Technology, Inc.
Cryolife, Inc.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Corvia Medical, Inc.
CardioKinetix, Inc.
Biomerics, LLC.
Lepu Medical Technology (Beijing) Co., Ltd.
XELTIS BV
Comed B.V.
HLT, Inc.
Meril Life Sciences Pvt. Ltd.
SYMETIS SA
Transcatheter Technologies GmbH
